Research
Metabolic adaptation
Tirzepatide treatment was associated with greater decreases in glycated hemoglobin and body weight compared to GLP-1 RA.
Practitioners can expect tirzepatide to be more effective in managing blood sugar and weight in patients with type 2 diabetes.
StrongSupportsmedium confidence
Treatment with tirzepatide was associated with greater decreases in glycated hemoglobin (treatment difference, -0.34 percentage points) and body weight (treatment difference, -2.9 kg) compared with GLP-1 RA.
Why this rating
Based on a large retrospective cohort study design.
Source
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Min‐Hsiang Chuang et al. · JAMA Network Open · 2024
DOI 10.1001/jamanetworkopen.2024.27258
cohort · n=140308Cited 106×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide treatment was associated with lower hazards of all-cause mortality compared to GLP-1 RA (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75).Strong
- Tirzepatide treatment was associated with lower hazards of major adverse cardiovascular events (MACEs) compared to GLP-1 RA (AHR, 0.80; 95% CI, 0.71-0.91).Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →